Lilly grabs Siemens’ tau tracers

Eli Lilly and Company has acquired a pair of PET tracers from Siemens. The investigational tracers are designed to target the tau deposits that are the hallmark of Alzheimer’s disease. Avid Radiopharmaceuticals, Lilly’s wholly owned subsidiary, will develop and validate the tracers, according to Lilly.